New Breast Cancer Drug Shows Promise in Tackling Treatment Resistance

SAN DIEGO, CA – May 18, 2026 – Biotheryx, Inc. today unveiled encouraging early-stage clinical data for a novel breast cancer drug, BTX-9341, offering a potential new line of defense for patients whose disease has progressed after standard therapies. The data, from a Phase 1 study, suggest the first-in-class "protein degrader" is not only effective in a heavily pretreated population but also boasts a remarkably favorable safety profile, a critical factor for patients with advanced disease.

The announcement provides a ray of hope in the challenging landscape of HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer, the most common subtype. For these patients, the development of resistance to current treatments is a near-certainty, creating a pressing unmet medical need that BTX-9341 aims to address.

The Challenge of Inevitable Resistance

The treatment paradigm for HR+/HER2- metastatic breast cancer was revolutionized over the last decade by the introduction of CDK4/6 inhibitors, such as palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). When combined with endocrine therapy, these drugs became the undisputed first-line standard of care, significantly extending the time before a patient's cancer progresses.

However, this success comes with a known endpoint. For nearly all patients, the cancer eventually finds ways to circumvent the drug's mechanism, leading to acquired resistance, typically within two to three years. When this happens, patients and their oncologists face a difficult crossroads with limited, and often less effective, subsequent treatment options.

Cancer cells develop resistance through various biological workarounds, including amplifying the production of proteins like CDK6 or activating alternative growth pathways involving Cyclin E and CDK2. This is where conventional inhibitors can fall short. BTX-9341 represents a new strategy, designed not just to block these cancer-driving proteins, but to eliminate them entirely.

A Profile of Safety and Efficacy

The data presented by Biotheryx stems from the dose escalation portion of its first-in-human Phase 1 trial. The study evaluated BTX-9341 both as a standalone therapy and in combination with fulvestrant, a standard endocrine therapy, in 28 patients with advanced HR+/HER2- breast cancer who had already received prior CDK4/6 inhibitor therapy.

What immediately stands out is the drug's tolerability. According to the company, there were no serious adverse events, and no patients had to stop treatment due to side effects. Hematological side effects were described as transient and reversible, and there were no significant non-hematological events.

"BTX-9341 has a highly favorable safety profile, with no clear evidence of key class related toxicities of other CDK4/6 inhibitors including gastrointestinal toxicities (diarrhea, nausea, vomiting), hepatotoxicity and prolongation of the QTc interval," stated Dr. Rachel M Layman of The University of Texas MD Anderson Cancer Center, an investigator in the study. This clean safety profile is crucial, as it could allow patients to stay on treatment longer and maintain a better quality of life.

Beyond safety, the drug showed clear signs of clinical activity in a patient population that had already exhausted multiple lines of therapy—some up to six. Among 24 evaluable patients, the Clinical Benefit Rate (CBR) was 41.7%. Even more impressively, in a smaller group of 10 patients representative of those who will be enrolled in the next phase of the trial, the CBR reached 80%. These results, which include prolonged partial responses and stable disease, are particularly noteworthy given the advanced state of the participants' cancer. The study is still ongoing, with some patients remaining on treatment for over a year, a testament to both the drug's tolerability and its durable effect.

A 'Degrader' vs. an 'Inhibitor': A New Weapon in the Arsenal

BTX-9341’s potential lies in its novel mechanism as a bifunctional protein degrader. Unlike traditional inhibitors that temporarily block a protein's function—like putting a key in a lock to jam it—degraders work by flagging the target protein for destruction by the cell's own waste disposal system. This approach results in the physical elimination of the target protein.

This is particularly relevant for overcoming resistance to older CDK4/6 inhibitors. BTX-9341 catalytically degrades both CDK4 and CDK6 proteins. Furthermore, it has a second, crucial function: it inhibits the downstream transcription of CDK2. This dual action is specifically engineered to counteract the very escape routes that cancer cells use to survive, such as the upregulation of CDK6 and the amplification of Cyclin E, which drives CDK2 activity.

"These encouraging clinical results mark an important milestone for our Phase 1 study evaluating BTX-9341," said Dr. Leah Fung, CEO of Biotheryx. "Given that CDK6 upregulation and Cyclin E amplification are established mechanisms of resistance to CDK4/6 inhibitors, these findings highlight the importance of degrading CDK4/6 and inhibiting downstream transcription of CDK2 to address convergent resistance mechanisms and may redefine the post-CDK4/6 inhibitor setting."

The Road Ahead for Biotheryx

Buoyed by these positive results, Biotheryx is moving forward with the Dose Expansion phase of the trial. This next stage will enroll up to 78 participants across the United States to further evaluate the efficacy and safety of BTX-9341 in combination with fulvestrant. The primary goal of this larger cohort will be to determine the Overall Response Rate (ORR), a more stringent measure of tumor shrinkage.

The journey from a Phase 1 trial to an approved drug is long and fraught with challenges. However, the unique mechanism, promising efficacy, and exceptional safety profile demonstrated so far position BTX-9341 as a significant contender in the high-stakes oncology market. For Biotheryx, a clinical-stage company built on the science of protein degradation, these results serve as a powerful validation of its proprietary PRODEGY platform.

As the dose expansion study gets underway, the oncology community will be watching closely. For the thousands of patients with HR+/HER2- breast cancer who will eventually see their disease progress beyond current standards of care, the advancement of innovative therapies like BTX-9341 represents a critical and tangible source of hope for the future.